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Background-—The early detection of cardiac syncope is challenging. We aimed to evaluate the diagnostic value of 4 novel
prohormones, quantifying different neurohumoral pathways, possibly involved in the pathophysiological features of cardiac
syncope: midregional–pro-A-type natriuretic peptide (MRproANP), C-terminal proendothelin 1, copeptin, and midregional-
proadrenomedullin.
Methods and Results-—We prospectively enrolled unselected patients presenting with syncope to the emergency department (ED) in
a diagnostic multicenter study. ED probability of cardiac syncope was quantified by the treating ED physician using a visual analogue
scale. Prohormones were measured in a blinded manner. Two independent cardiologists adjudicated the final diagnosis on the basis
of all clinical information, including 1-year follow-up. Among 689 patients, cardiac syncope was the adjudicated final diagnosis in 125
(18%). Plasma concentrations of MRproANP, C-terminal proendothelin 1, copeptin, and midregional-proadrenomedullin were all
significantly higher in patients with cardiac syncope compared with patients with other causes (P<0.001). The diagnostic accuracies
for cardiac syncope, as quantified by the area under the curve, were 0.80 (95% confidence interval [CI], 0.76–0.84), 0.69 (95% CI,
0.64–0.74), 0.58 (95% CI, 0.52–0.63), and 0.68 (95% CI, 0.63–0.73), respectively. In conjunction with the ED probability (0.86; 95%
CI, 0.82–0.90), MRproANP, but not the other prohormone, improved the area under the curve to 0.90 (95% CI, 0.87–0.93), which was
significantly higher than for the ED probability alone (P=0.003). An algorithm to rule out cardiac syncope combining an MRproANP
level of <77 pmol/L and an ED probability of <20% had a sensitivity and a negative predictive value of 99%.
Conclusions-—The use of MRproANP significantly improves the early detection of cardiac syncope among unselected patients
presenting to the ED with syncope.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01548352. ( J Am Heart Assoc. 2017;6:
e006592. DOI: 10.1161/JAHA.117.006592.)
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ORIGINAL RESEARCH
S yncope is a transient loss of consciousness associatedwith an inability to maintain postural tone attributable to
global cerebral hypoperfusion.1,2 Syncope is common and
represents 1% to 2% of all emergency department (ED) visits.3
Establishing the cause is challenging and, therefore, generally
time and resource consuming. In the United States, 30% to
40% of such patients are subsequently admitted for further
investigation at an annual cost of $2.4 billion, according to
the Medicare database.4 The risk of death is doubled among
patients with cardiac syncope in comparison to other
causes.5,6 Identification of these patients is, therefore, crucial.
Several risk scores,7–9 and the establishment of specialized
syncope units10,11 in the ED, were proposed to improve the
diagnostic yield to identify patients at risk of an adverse
outcome. However, these tools have not been implemented in
most institutions, at least in part because of their perceived
complexity. Therefore, the rapid and accurate detection of
cardiac syncope in the ED remains an unmet clinical need.
We hypothesized that blood biomarkers might provide
incremental diagnostic value in the rapid and accurate detec-
tion of cardiac syncope in the ED, similar to the contribution
that they have made for other common presenting symptoms,
such as acute chest pain12–15 and acute dyspnea.16–18
It is challenging to find a biomarker that could represent the
“memory of the cardiac or arrhythmic event” at ED presenta-
tion, when the patient has again become asymptomatic and
hemodynamically stable. The recent development and clinical
introduction of assays that reliably quantify stable prohormone
fragments, rather than the more unstable active hormone, have
provided a new and unique diagnostic window.19,20 Using this
concept, immunoassays targeting 4 prohormone fragments,
including midregional–pro-A-type natriuretic peptide
(MRproANP), C-terminal proendothelin 1 (CTproET1), copeptin,
and midregional-proadrenomedullin (MRproADM), were devel-
oped and applied in several clinical settings.18–23 These
prohormones allow us to quantify the activation of 4 distinct
cardiovascular and biochemical pathways possibly involved in
either the pathophysiological features of syncope or the
endogenous response to it.18–24 As a first hint about the
possible role of these prohormones in syncope, CTproET1
plasma concentrations were associated with malignant
arrhythmias in patients with chronic heart failure.25
We, therefore, performed a large international study evalu-
ating the diagnostic utility of MRproANP, CTproET1, copeptin,
and MRproADM in patients presenting with syncope to the ED.
Methods
Study Design, Setting, and Selection of
Participants
BASEL IX (Basel Syncope Evaluation Study) is an ongoing,
prospective, international, diagnostic, multicenter study
enrolling unselected patients in 13 hospitals in 8 countries
(Switzerland, Spain, Germany, Italy, Poland, New Zealand,
Australia, and the United States) on 3 continents (Europe,
Australia, and North America; Table S1). The study is designed
to contribute to improving the management of patients
presenting with syncope. Patients aged >40 years presenting
to the ED with syncope within the past 12 hours were
recruited, after written informed consent was obtained.
For this analysis, the exclusion criteria included patients
with missing prohormone fragment measurements, patients
with a final diagnosis of a nonsyncopal loss of consciousness,
and those in whom the final diagnosis remained unclear even
after central adjudication. The study was performed according
to the principles of the Declaration of Helsinki preregistered
and was approved by the local ethics committees. The
authors designed the study, gathered and analyzed the data
according to the Standards for the Reporting of Diagnostic
Accuracy Studies guidelines for studies of diagnostic accuracy
(Data S1), vouch for the data and analysis, wrote the article,
and made the decision to submit the article for publication.
Routine Clinical Assessment
Two sets of data were obtained: (1) by the treating ED
physician as part of routine clinical care, according to local
Clinical Perspective
What Is New?
• This is the first prospective analysis assessing the diagnos-
tic role of 4 novel prohormones in patients presenting with
syncope to the emergency department.
• Diagnostic accuracy of midregional–pro-A-type natriuretic
peptide for cardiac origin among unselected patients
presenting with syncope to the emergency department is
high and provides significantly incremental diagnostic value
on top of clinical judgement and a recommended risk
stratification tool.
What Are the Clinical Implications?
• An algorithm based on the combination of midregional–pro-
A-type natriuretic peptide and clinical judgement allowed us
to rule out the presence of cardiac syncope with a
sensitivity of 99% and a negative predictive value of 99%
and may, therefore, improve patient care and logistics.
• Although this study represents an important step towards
the integration of biomarkers into the clinical management
of patients presenting with syncope to the emergency
department, external validation in a large diagnostic study of
comparable methodological scrutiny is required.
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standard operating procedures; and (2) by an experienced
research fellow, using standardized case report forms
uniformly collecting predefined details of patient history, the
circumstances of syncope, and physical examination findings.
A digital 12-lead ECG was recorded at presentation and stored
electronically. Clinical judgment by the ED physician about the
presence of cardiac syncope was quantified using a visual
analogue scale ranging from 0% to 100%. The treating ED
physician estimated cardiac origin probability on the basis of
all information available in the individual patient 90 minutes
after presentation, including clinical assessment, the 12-lead
ECG, and the routine laboratory test results (but not the ones
assessed for the study). To also provide a comparison with a
recommended standard, the “Evaluation of Guidelines in
Syncope Study” (EGSYS) risk score was calculated (Data
S1).1,2 Clinical decisions were absolutely independent of the
present study. All participating centers were using standard-
ized operating procedures for the diagnostic workup of
patients presenting with syncope to the ED, according to
current European Society of Cardiology Guidelines.2
Biochemical Measurements
Immediately after informed consent was obtained, venous
blood was obtained in EDTA plastic tubes, centrifuged, and
stored at 80°C. Measurement of MRproANP, CTproET1,
copeptin, and MRproADM was performed in a blinded
manner in a dedicated core laboratory using validated
sandwich immunoassays (Brahms, Hennigsdorf/Berlin, Ger-
many).26–29 In a subgroup of patients, B-type natriuretic
peptide (BNP) was measured as part of the local clinical
standardized operating procedures for patients with syncope
from fresh plasma using the Architect system (Abbott,
Chicago, IL).
Follow-Up and Adjudicated Final Diagnosis
Patients were contacted 12 and 24 months after discharge by
telephone or in written form. Information about recurrent
syncope, hospitalization, and cardiac events during follow-up
was further obtained from the patient’s hospital notes, the
family physician’s records, and national registries on mortal-
ity, where possible. To determine the final diagnosis of the
index syncopal event in each patient, 2 independent cardiol-
ogists reviewed all available medical records from both data
sets: the clinical data set and the study-specific data set after
at least 12 months of follow-up. The clinical data set included
the clinical history, findings on physical examination, results
of routine laboratory tests, radiologic testing results, ECG
findings, and, if available, Holter-ECG, external and implan-
table loop device, echocardiography, cardiac exercise test,
Schellong test, tilt table testing, coronary angiography,
electrophysiological examination, pacemaker control, and
further investigation findings during recurrent hospitalizations
or ambulatory treatment. A detailed overview of all performed
diagnostic tests is given in Table S2. Study-specific data
included standardized forms uniformly collecting predefined
details of patient history, the circumstances of syncope, the
physical examination findings, and at least 12 months of
follow-up data. In situations of adjudicator disagreement
about the diagnosis, cases were reviewed and adjudicated in
conjunction with a third cardiologist. Predefined categories
for the adjudication included cardiac syncope, reflex syncope,
orthostatic syncope, other noncardiac syncope, and unknown
cause of syncope (Table S3). According to guidelines,2 cardiac
causes of syncope were defined as supraventricular or
ventricular arrhythmias, severe structural heart diseases (eg,
hypertrophic cardiomyopathy or valvular diseases), pericardial
tamponade, congenital myocardial or valvular anomalies,
aortic dissection, or acute pulmonary hypertension (eg,
attributable to pulmonary embolism), leading to a transient
loss of consciousness. It is important to highlight that the
presence of cardiac disease (eg, coronary artery disease) was
not at all sufficient for the adjudication to a cardiac cause of
syncope. The detailed reconstruction of the syncopal event
with the study-specific data set and third-party anamnesis,
and long-term follow-up on cardiovascular events and/or
recurrent syncope, were critical pillars of the adjudication.
Further details on the adjudication are given in Data S1.
Statistical Analysis
Continuous variables are presented as meanSD when
normally distributed and median with 25th and 75th per-
centiles when nonnormally distributed. Categorical variables
are expressed as numbers and percentages. The Mann-
Whitney U test was applied for comparison of continuous
variables between cardiac and noncardiac syncope, and
categorical variables were compared by Pearson v2 test and
Fisher exact test, as appropriate. We calculated the sample
size on the basis of our previous experiences with studies on
the diagnosis of acute myocardial infarction in patients
presenting with chest pain to the ED12–15,30,31 and aimed to
enroll a total of 120 patients with cardiac syncope. Using the
nomogram of Carley et al and Jones et al,32,33 the targeted
sample size ranged from 660 to 940 patients, estimating a
sensitivity of 90% with a 2-sided 95% confidence interval (CI)
of 5% to detect cardiac syncope. To evaluate diagnostic
accuracy for the diagnosis of cardiac syncope, receiver-
operating characteristic curves were constructed to assess
the sensitivity and specificity of the ED physician’s clinical
judgment and the EGSYS risk score for cardiac origin
probability, alone and in combination with MRproANP,
CTproET1, copeptin, and MRproADM. The comparison of
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areas under the receiver-operating characteristic curves
(AUCs) was performed according to DeLong et al.34 In
addition, reclassification tables for net reclassification
improvement were used to assess the incremental yield of
the additional use of MRproANP at presentation to predict
cardiac syncope.35 Logistic regression was used to combine
clinical judgement with prohormone plasma concentrations in
predicting the final adjudicated diagnosis, generating a
graphic displayed as a cardiac syncope diagnosis nomogram.
Glomerular filtration rate was calculated using the Chronic
Kidney Disease Epidemiology Collaboration equation.36
All hypothesis testing was 2 tailed, and P<0.05 was
considered statistically significant. Statistical analyses were
performed using IBM SPSS Statistics for Windows, version
22.0 (SPSS Inc, Chicago, IL) and R 3.3.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Characteristics of Study Subjects
Eight-hundred eighty-six consecutive patients were enrolled
in the BASEL IX study (Figure S1) from May18th, 2010 until
July 25th, 2014. A complete screening log was not kept in
all participating sites. In those sites with a screening log,
14% of presenting patients were excluded because they
presented to the ED >12 hours after the syncopal event. For
this analysis, patients with missing prohormone fragment
measurements (n=3), those with a final diagnosis of a
nonsyncopal loss of consciousness (n=117), and individuals
in whom the final diagnosis remained unclear even after
central adjudication (n=77) were excluded, leaving 689
patients for the analysis. A complete follow-up at 12 months
was available in 99% of patients and at 24 months in 89% of
patients.
Patients with cardiac syncope were significantly older,
more often had a history of coronary artery disease,
arrhythmia, or valvular heart disease, and more often
experienced syncope during exertion. Further details on
patient demographics are provided within Table 1.
Adjudicated Final Diagnosis of Syncope
The overall patient population had the following adjudicated
syncope causes: 125 (18%) cardiac, 320 (46%) reflex (neurally
mediated), 181 (26%) orthostatic hypotension, and 63 (9%)
other noncardiac causes. Among patients with cardiac
syncope, most (90 [13%]) experienced arrhythmias, of which
58 (8.4%) were bradyarrhythmias and 27 (3.9%) were
tachyarrhythmias. Twenty-eight patients (4.1%) had structural
heart disease, including acute myocardial infarction in 13
(1.9%); in 7 patients (1%), other cardiac origin triggered
syncope (eg, pulmonary embolism). All final adjudicated
diagnoses are listed in Table S3.
Prohormone Plasma Concentrations According to
Adjudicated Diagnosis
Plasma concentrations of MRproANP, CTproET1, copeptin,
and MRproADM were all significantly higher among patients
with cardiac syncope compared with patients with other
adjudicated causes of syncope (Table 2, Figure 1).
Diagnostic Performance
The diagnostic accuracy of MRproANP levels for determining a
cardiac syncope cause, as quantified by the AUC curve, was
0.80 (95% CI, 0.76–0.84; Figure 2). Diagnostic performance
measures of receiver-operating characteristic curve–derived
cutoff points achieving predefined target sensitivities for rule
out and rule in are summarized in Tables 3 and 4. At a
threshold of <77 pmol/L, MRproANP ruled out 30% of
individuals (n=211), with a sensitivity of 95% and a negative
predictive value of 97%. An algorithm to rule out cardiac
syncope, combining an MRproANP level of <77 pmol/L and
an ED probability of <20%, had a sensitivity of 99% and a
negative predictive value of 99% and allowed us to triage 18%
of patients toward rule out. At a threshold of >181 pmol/L,
MRproANP ruled in 28% of individuals (n=192), with a
specificity of 80% and a positive predictive value of 41%. An
algorithm to rule in cardiac syncope, combining an MRproANP
level of >181 pmol/L and an ED probability of >80%, had a
specificity of 98% and a positive predictive value of 81% and
allowed us to triage 8% of patients toward rule in.
The diagnostic accuracy for the other prohormone markers
for detecting cardiac syncope, presented as AUC, was 0.69
(95% CI, 0.64–0.74) for CTproET1, 0.58 (95% CI, 0.52–0.63)
for copeptin, and 0.68 (95% CI, 0.63–0.73) for MRproADM.
The combination of CTproET1 and MRproANP did not improve
diagnostic accuracy compared with that of MRproANP alone
(P=0.90).
Combination of Overall Clinical Judgement With
MRproANP
The AUC for the combination of ED probability with
MRproANP was significantly higher (0.90; 95% CI, 0.87–
0.93) than for the ED probability alone (AUC, 0.86; 95% CI,
0.82–0.90; P=0.003). The net reclassification improvement of
MRproANP was calculated at 0.216 (P<0.001). Integrated
discriminatory improvement was 0.035 (P=0.001; Table S4).
The combination of the other prohormones with ED probabil-
ity did not provide a significant improvement in diagnostic
accuracy when compared with ED probability alone
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Syncope (n=564) P Value
Age, y 70 (57–80) 77 (68–84) 68 (54–78) <0.001
Time to presentation, min 75 (50–127) 81 (52–150) 75 (50–122) 0.379
Time to blood draw
since presentation, min
107 (70–159) 109 (75–162) 107 (70–159) 0.682
Time to blood draw since
syncopal event, min
190 (140–290) 187 (156–298) 190 (137–289) 0.464
Male sex 404 (58.6) 76 (60.8) 328 (58.2) 0.658
Inpatient treatment 368 (53.4) 106 (84.8) 262 (46.5) <0.001
Time hospitalized, d 4 (1–8) 6 (2–9) 3 (1–7) <0.001
Risk factors
Hypertension 393 (57.1) 79 (63.7) 314 (55.7) 0.124
Hypercholesterolemia 262 (39.3) 57 (47.9) 205 (37.5) 0.045
Diabetes mellitus 98 (14.2) 25 (20.2) 73 (12.9) 0.052
Current smoking 130 (19.0) 15 (12.3) 115 (20.4) 0.051
History of smoking 218 (31.8) 43 (35.2) 175 (31.1) 0.431
History
Coronary artery disease 149 (21.9) 45 (37.2) 104 (18.6) <0.001
Previous MI 92 (13.4) 28 (22.4) 64 (11.3) 0.002
Arrhythmia* 138 (20.5) 43 (35.5) 95 (17.2) <0.001
Valvular heart disease 63 (9.3) 22 (18.0) 41 (7.4) <0.001
Previous stroke 48 (7.0) 9 (7.3) 39 (7.0) 1
Epilepsy 19 (2.8) 2 (1.6) 17 (3.0) 0.551
Previous syncope 413 (61.4) 74 (59.7) 339 (61.7) 0.745
Syncope situation
Orthostatic 83 (12.3) 8 (6.5) 75 (13.6) 0.043
While standing 271 (40.2) 50 (40.7) 221 (40.1) 0.993
Exertion 76 (11.3) 32 (26.2) 44 (8.0) <0.001
While sitting 256 (37.9) 41 (33.6) 215 (38.9) 0.325
While lying down 22 (3.3) 3 (2.5) 19 (3.4) 0.781
Presence of injury 97 (14.5) 18 (15.0) 79 (14.4) 0.983
Vital parameters
Heart rate 72 (64–84) 73 (60–92) 72 (64–82) 0.509
Systolic BP 129 (114–145) 131 (117–152) 128 (114–144) 0.062
Diastolic BP 73 (62–82) 73 (60–84) 73 (63–81) 0.972
Pathological ECG† 240 (34.8) 72 (57.6) 168 (29.8) <0.001
Long-term medication
Aspirin 242 (32) 52 (41) 190 (29.5) 0.013
Vitamin K antagonists 92 (12) 26 (21) 66 (10.3) 0.002
b-Blockers 256 (33) 54 (43) 202 (31.4) 0.017
Antiarrhythmics 26 (3.4) 7 (5.6) 19 (3.0) 0.227
ACEIs/ARBs 333 (43) 66 (52) 267 (41.5) 0.031
Continued
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(CTproET1, P=0.05; copeptin, P=0.09; and MRproADM,
P=0.08, for the comparisons of ED probability plus biomarker
versus ED probability alone).
Cardiac Syncope Using the Fagan Nomogram
Figure 3 is a Fagan nomogram for cardiac syncope to
visualize the additive value of MRproANP to clinical judge-
ment. As indicated by the nomogram, MRproANP has the
greatest value as a diagnostic test in patients with interme-
diate pretest probability. In this category (visual analogue
scale score ≥10% and ≤60%), 34 of 424 patients (8%)
experienced cardiac syncope. MRproANP ≥175 pmol/L cor-
rectly classified 77% of all patients as having cardiac syncope
or not having cardiac syncope. In 358 patients with a low ED
probability of cardiac syncope (≤20%), 12 of 358 (3.4%) had a
final adjudicated diagnosis of cardiac syncope. Of these 12
individuals, 11 (99.3%) could have had the misdiagnosis
corrected if the additional information of MRproANP
≥77 pmol/L had been available. Specific patient characteris-
tics of these 11 patients are provided in Table S5. A diagnosis
other than cardiac syncope was initially suspected in the ED
in the presence of prodromal symptoms (8 of 11 patients) and
a normal ECG at presentation (7 of 11 patients) or in the
absence of cardiac risk factors, such as diabetes mellitus (2 of
11 patients) or hypertension (3 of 11 patients).
Combination of MRproANP With EGSYS Risk
Score
The diagnostic accuracy of MRproANP levels in combination
with the EGSYS risk score in detecting cardiac syncope is
shown in Figure 2. The AUC for the combination of MRproANP
and the EGSYS risk score was significantly higher (0.81; 95%
CI, 0.77–0.85) than for the EGSYS risk score alone (AUC,
0.67; 95% CI, 0.63–0.72; P<0.001).
Prediction of Cardiac Syncope
Logistic regression analysis confirmed MRproANP as a
predictor of cardiac syncope in both univariate and multivari-
ate analyses (Table 5). In multivariable analysis, only a
pathological ECG (according to the European Society of









Syncope (n=564) P Value
Calcium antagonists 130 (17) 23 (18) 107 (16.6) 0.755
Diuretics 222 (29) 56 (44) 166 (25.8) <0.001
Nitroglycerine 44 (5.7) 14 (11) 30 (4.7) 0.008
Data are presented as median (25th–75th percentile) or number (percentage). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood
pressure; and MI, myocardial infarction.
*Arrhythmia indicates history of supraventricular or ventricular tachycardia.
†Pathological ECG was defined as meeting at least one of the following criteria: bifascicular block (left bundle branch block or right bundle branch block [RBBB] combined with left anterior
fascicular block), second- or third-degree AV block, asymptomatic inappropriate sinus bradycardia (<50 beats/min) in the absence of negatively chronotropic medications, nonsustained
ventricular tachycardia, preexcited QRS complexes, long or short QT intervals (men, >450 ms; women, >470 ms), RBBB pattern with ST elevation in leads V1 to V3 (Brugada syndrome),
early repolarization, Q waves suggesting myocardial infarction, negative T waves in right precordial leads, and e waves and ventricular late potentials suggestive of arrhythmogenic right
ventricular dysplasia.2








MRproANP, pmol/L 246 (141–355) 91 (59–146) 122 (72–197) 111 (62–189) <0.001
CTproET1, pmol/L 89 (65–118) 61 (53–75) 80 (59–104) 65 (52–83) <0.001
Copeptin, pmol/L 45 (20–78) 32 (14–64) 33 (14–72) 18 (10–52) 0.01
MRproADM, nmol/L 1.0 (0.7–1.4) 0.6 (0.5–0.9) 0.9 (0.7–1.2) 0.7 (0.6–1.0) <0.001
Data are given as median (25th–75th percentile). MRproANP: In healthy individuals, the range of MRproANP concentrations was from 9.6 to 313 pmol/L. The median was 45 pmol/L. The
99th percentile was 197.5 pmol/L.26 CTproET1: In healthy individuals, the range of CTproET1 concentrations was from 10.5 to 77.4 pmol/L, and the mean (SD) was 44.3 (10.6) pmol/L.
The 99th percentile was 72.8 pmol/L.27 Copeptin: In healthy individuals, the range of copeptin concentrations was from 1 to 13.8 pmol/L. The median was 4.2 pmol/L. The 99th
percentile was 13.5 pmol/L.29 MRproADM: In healthy individuals, the range of MRproADM concentrations was from 0.10 to 0.64 nmol/L, and the mean (SD) was 0.33 (0.07) nmol/L. The
99th percentile was 0.52 nmol/L.28 CTproET1 indicates C-terminal proendothelin 1; MRproADM, midregional-proadrenomedullin; and MRproANP, midregional–pro-A-type natriuretic
peptide.
*The P values were tested for the comparison across the 4 categories in the table. The Kruskal-Wallis test was used to conduct this test.
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MRproANP (odds ratio, 4.51; 95% CI, 2.84–7.16) were
independent predictors of cardiac syncope.
Direct Comparison of MRproANP With BNP
In the subgroup of patients with both biochemical signals
available (n=393 [57%]), the AUC was 0.77 (95% CI, 0.71–
0.83) for MRproANP and 0.74 (95% CI, 0.68–0.81) for BNP
(P=0.278) for detecting cardiac syncope.
Discussion
This prospective multicenter study using long-term follow-up
and central adjudication aimed to contribute to advancing the
rapid and accurate diagnosis of patients presenting with
syncope to the ED. The study evaluated the diagnostic utility
of prohormones quantifying 4 different neurohumoral path-
ways possibly involved in the pathophysiological characteris-
tics of cardiac syncope. Prohormones were selected on the
basis of the hypothesis that they could represent the
“memory of the cardiac and in fact often arrhythmic event”
at ED presentation and because commonly they are more
stable analytically compared with active hormones.16–18
We report 7 major findings: First, in patients with an
adjudicated diagnosis of cardiac syncope, prohormone
plasma levels (MRproANP, CTproET1, copeptin, and
MRproADM) were significantly higher than in patients with
noncardiac causes of syncope. Second, although MRproANP
Figure 1. Box plots for all assessed prohormones in patients with a different origin of syncope. The ends of the whisker were defined so that
the maximum length of each whisker is 1.5 times the interquartile range. Midregional–pro-A-type natriuretic peptide (MRproANP): In healthy
individuals, the range of MRproANP concentrations was from 9.6 to 313 pmol/L. The median was 45 pmol/L. The 99th percentile was
197.5 pmol/L.26 C-terminal proendothelin 1 (CTproET1): In healthy individuals, the range of CTproET1 was from 10.5 to 77.4 pmol/L, and the
mean (SD) was 44.3 (10.6) pmol/L. The 99th percentile was 72.8 pmol/L.27 Copeptin: In healthy individuals, the range of copeptin
concentrations was from 1 to 13.8 pmol/L. The median was 4.2 pmol/L. The 99th percentile was 13.5 pmol/L.29 Midregional-
proadrenomedullin (MRproADM): In healthy individuals, the range of MRproADM was from 0.10 to 0.64 nmol/L, and the mean (SD) was
0.33 (0.07) nmol/L. The 99th percentile was 0.52 nmol/L.28
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levels were nearly exclusively elevated in patients with cardiac
syncope, CTproET1 and MRproADM levels were also elevated
in patients with syncope attributable to orthostatic hypoten-
sion. Third, diagnostic accuracy for cardiac syncope of
prohormones, as quantified by the AUC curve, was high for
MRproANP, moderate for CTproET1 and MRproADM, and poor
for copeptin. Fourth, MRproANP provided significant incre-
mental value when combined with clinical judgment in the ED,
which was mainly based on the clinical assessment and the
12-lead ECG. Diagnostic accuracy for the combination of
MRproANP and ED probability was high (AUC, 0.90; 95% CI,
0.87–0.93) and significantly higher than for ED probability
alone. Although the 0.04 higher C-statistic represents a
modest increase, a confirmed diagnosis in a population
fraught with diagnostic uncertainty suggests important poten-
tial clinical utility. MRproANP concentrations might add
information of a more objective and more specific marker of
heart disease than a subjective clinical history or examination
alone. An algorithm incorporating MRproANP levels seems to
perform better than existing protocols based on international
syncope guidelines1,2 (eg, the substantial incremental value of
MRproANP was confirmed using the EGSYS risk score as an
alternative method of reflecting the standard of care). The
magnitude of the increase in diagnostic accuracy provided by
MRproANP was identical compared with the increase in
diagnostic accuracy in the diagnosis of myocardial infarction
provided by high-sensitivity cardiac troponin compared with
sensitive cardiac troponin.37 None of the other biochemical
signals provided incremental value on top of clinical judgment.
Fifth, increased MRproANP levels were independently asso-
ciated with cardiac causes of syncope (odds ratio, 4.51; 95%
CI, 2.84–7.16) and were a stronger predictor than clinical
features. Sixth, an algorithm based on the combination of
MRproANP and clinical judgement allowed use to rule out the
presence of cardiac syncope, with a sensitivity of 99% and a
negative predictive value of 99%. Seventh, subgroup analysis
in patients in whom BNP was measured as part of the clinical
standardized operating procedures documented comparable
diagnostic accuracy of MRproANP and BNP. This suggests
that our findings about the incremental diagnostic value of
MRproANP likely can be extrapolated to BNP. Further studies
are warranted to appropriately test this hypothesis.
These findings extend and corroborate previous pilot data
on the possible clinical utility of biomarkers quantifying
neurohormonal pathways.22,38–42 Several studies have
demonstrated that ANP and BNP plasma concentrations are
increased in heart failure and cardiac arrhythmias.43–45 For
example, in a pilot study of 18 patients, a significant increase
Figure 2. Receiver-operating characteristic (ROC) curves for detection of cardiac syncope for midregional–pro-A-type natriuretic peptide
(MRproANP), alone and in combination with either clinical judgement (left) or Evaluation of Guidelines in Syncope Study (EGSYS) risk score
(right). ROC curves for the diagnostic performance of MRproANP, alone and in combination with either clinical judgment (left) or EGSYS risk
score (right), for diagnosing cardiac syncope. The red curve displays the biomarker alone; the green curve, emergency department (ED)
probability (visual analogue scale [VAS]; left) or EGSYS risk score (right) for detecting cardiac syncope; and the blue curve, the combination of
the biomarker and ED probability (left) or EGSYS risk score (right). The black arrows show the comparison of areas under the ROC curves (AUCs)
for the combination of ED probability with MRproANP against ED probability alone (left) and for the combination of EGSYS risk score with
MRproANP against the EGSYS risk score alone (right). CI indicates confidence interval.
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of BNP and NT-proBNP (N-terminal pro-B-type natriuretic
peptide) plasma concentrations was observed after the
induction of ventricular fibrillation in patients with an
implantable cardioverter defibrillator.45 Accordingly, BNP
and NT-proBNP have been proposed to help identify patients
with syncope of cardiac origin and to be good markers for risk
stratification in this population.8,39,46–48 Finally, retrospective
single-center studies reported higher BNP and NT-pro-BNP
levels in patients admitted for syncope to a cardiology
department in whom a cardiac cause was found during
in-hospital workup compared with other causes.31,45
Detection of cardiac syncope has immediate conse-
quences for patient management and, in general, triggers
hospital admission, ECG-rhythm monitoring, and cardiology
consultation.1,2 ECG-rhythm monitoring is mandatory because
the next episode of bradyarrhythmia or tachyarrhythmia may
be fatal if undetected and untreated.1,2 Cardiology consulta-
tion is necessary for the rapid initiation of the appropriate
further diagnostic and therapeutic measures. These include
implantation of a pacemaker in patients with documented
symptomatic bradycardia (eg, high-degree AV block) and
transthoracic echocardiography in patients with suspected
severe aortic stenosis, followed by coronary angiography and
computed tomography–angiography once severe aortic
stenosis is confirmed in the preparation of aortic valve
replacement. They also include implantation of a cardioverter-
defibrillator in patients with coronary artery disease and
severely impaired left ventricular ejection fraction or further
risk stratification by an electrophysiological study for the
assessment of ventricular arrhythmias. Moreover, if the risk of
recurrence of a cardiac syncope is estimated to be high (eg, in
patients with intermittent high-degree AV block), bed rest
would seem prudent to avoid the possible harm of injuries
related to falls in case of recurrence.
Our findings suggest that plasma levels of MRproANP can
be considered a marker of cardiac syncope. Therefore,
MRproANP can possibly offer diagnostic information that
would improve management of syncopal patients in the ED.
As demonstrated by the nomogram, and by proposing an
algorithm implementing the combination of a low ED
probability and low plasma levels of MRproANP (with
sensitivity and negative predictive values of 99% for cardiac
syncope), the benefits of MRproANP application may be
predominately in ruling out a cardiac cause of syncope and
defining low-risk patients suitable for outpatient manage-
ment. Avoiding unnecessary hospital admissions and exten-
sive cardiac workup by a more accurate diagnosis likely will
result in cost savings. This approach mirrors the use of
D-dimers in the rule out of venous thromboembolism.49
Further studies specifically addressing cost-effectiveness of
MRproANP are warranted to evaluate whether the cost
savings of the biomarker-guided approach are similar to cost
savings observed with the use of natriuretic peptides in
patients presenting with acute dyspnea.50,51
Table 3. Diagnostic Test Characteristics of Prespecified Cut Point Values for Rule Out of Cardiac Syncope
Target
Sensitivity, % No. (%) of Patients
Cut Point for MRproANP,
pmol/L Sensitivity, % Specificity, % NPV, % PPV, % Accuracy, %
70 450 (65) <159 70 (62–78) 73 (69–77) 92 (90–94) 37 (33–41) 72 (69–76)
80 380 (55) <130 80 (73–87) 63 (59–67) 94 (91–96) 33 (30–36) 63 (63–70)
90 289 (42) <98 90 (85–94) 49 (45–53) 96 (93–98) 28 (26–30) 56 (53–60)
95 211 (31) <77 95 (91–98) 36 (32–40) 97 (95–99) 25 (24–26) 47 (44–50)
Combination 124 (18) <77 (VAS score, <20%) 99 (96–100) 22 (19–26) 99 (96–100) 22 (19–25) 36 (32–39)
Numbers represent percentage (95% confidence interval) unless otherwise indicated. MRproANP indicates midregional–pro-A-type natriuretic peptide; NPV, negative predictive value; PPV,
positive predictive value; and VAS, visual analogue scale.
Table 4. Diagnostic Test Characteristics of Prespecified Cut Point Values for Rule In of Cardiac Syncope
Target Specificity, % No. (%) of Patients
Cut Point for MRproANP,
pmol/L Sensitivity, % Specificity, % NPV, % PPV, % Accuracy, %
70 262 (38) >147 74 (66–82) 70 (66–74) 92 (90–94) 35 (31–39) 71 (67–74)
80 192 (28) >181 63 (54–71) 80 (77–83) 91 (89–93) 41 (36–47) 77 (74–80)
90 121 (18) >243 51 (42–60) 90 (88–93) 89 (88–91) 53 (46–62) 83 (81–86)
95 55 (8) >373 22 (14–29) 95 (93–97) 85 (83–86) 49 (37–62) 82 (80–84)
Combination 53 (8) >181 (VAS score, >80%) 34 (27–43) 98 (97–99) 81 (69–90) 87 (84–90) 87 (84–89)
Numbers represent percentage (95% confidence interval) unless otherwise indicated. MRproANP indicates midregional–pro-A-type natriuretic peptide; NPV, negative predictive value; PPV,
positive predictive value; and VAS, visual analogue scale.
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Further studies are also necessary to decipher the exact
pathophysiological link between the vasoconstrictor prohor-
mone CTproET1 and the vasodilator prohormone MRproADM
and orthostatic hypotension.
Most patients presenting with syncope to the ED had
mildly elevated plasma concentrations of copeptin, a stable
peptide derived from the precursor of vasopressin, irrespec-
tive of the cause of syncope. This suggests that the arginine-
vasopressin system may be activated to a similar extent by
several mechanisms leading to syncope. Accordingly, copep-
tin does not seem to have a role as a diagnostic biomarker in
this setting.41,52
This study has 3 important methodological strengths that
differentiate it from previous studies on syncope: global
representation of patients attributable to enrollment in 8
countries on 3 continents, long-term follow-up, and central
adjudication by 2 independent cardiologists to maximize the
accuracy of the reference standard diagnosis of cardiac
versus noncardiac syncope.
Although this study represents an important step towards
the integration of biomarkers into the clinical management of
patients presenting with syncope to the ED, external valida-
tion in a large diagnostic study of comparable methodological
scrutiny is required.
This applies to the diagnostic accuracy of MRproANP in
general and the suggested cutoff levels for early rule out in
particular. Because patients with syncope show a wide age
range (44–94 years in this study), an even larger data set may
allow derivation of age-optimized cutoff levels to further
improve the sensitivity and/or the effectiveness of the
biomarker-based rule-out approach.53 Also, additional studies
are warranted to evaluate other biochemical and/or electro-
cardiographic signatures, in combination with clinical judg-
ment, to improve the early diagnosis of cardiac syncope.
These studies are needed because diagnostic uncertainties in
patients presenting to the ED with syncope have become the
focus of debate about inappropriate use of resources,
Figure 3. Cardiac syncope diagnosis nomogram. Clinical judg-
ment by the emergency department (ED) physician about the
presence of cardiac syncope is displayed as “Pre.” The treating ED
physician estimated cardiac origin probability on the basis of all
information available in the individual patient 90 minutes after
presentation, including clinical assessment, the 12-lead ECG, and
the routine laboratory test results. The middle line represents
midregional–pro-A-type natriuretic peptide (MRproANP) level (in
pmol/L) at presentation. When a straight line is drawn through
the pretest probability and MRproANP level, the posttest prob-
ability is found on the right line (“Post”). For example, an ED
probability of 50% with an MRproANP level of 1000 pmol/L yields
an 78% probability of cardiac syncope on the basis of these 2
predictors (blue-dotted line).
Table 5. Logistic Regression
Variable
Univariable Logistic Regression Multivariable Logistic Regression
Odds Ratio 95% CI (Lower-Upper) P Value Odds Ratio 95% CI (Lower-Upper) P Value
Age* 1663 1412 1958 <0.001 1293 1012 1654 0.040
Male sex 1124 757 1669 0.535
Valvular disease 2747 1569 4809 <0.001 1726 901 3307 0.01
Charlson comorbidity index 1252 1164 1347 <0.001
Palpitations 1025 502 2093 0.945
ECG pathological 3236 2176 4812 <0.001 2020 1268 3218 0.003
GFR, CKD-EPI 981 973 989 <0.001 1023 1008 1038 0.002
MRproANP (ln transformed) 4569 3329 6271 <0.001 4506 2837 7156 <0.001
CTproET1 (ln transformed) 5522 3380 9022 <0.001 1700 765 3744 0.193
CI indicates confidence interval; CKD-EPI indicates Chronic Kidney Disease Epidemiology Collaboration; CTproET1, C-terminal proendothelin 1; GFR, glomerular filtration rate; ln, natural
log; and MRproANP, midregional–pro-A-type natriuretic peptide.
*Per 10-year increase.
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increasing healthcare costs, and, most important, patient
safety.54,55
Potential limitations of the present study merit considera-
tion. First, this diagnostic study using central adjudication
required informed consent. This may have introduced a small,
but unavoidable, selection bias. Because this study enrolled all
patients presenting with syncope to the ED, irrespective of the
pretest probability for a cardiac cause, any selection bias should
have beenminimized. Second, we recruited patients presenting
to the ED. Therefore, it is unknown whether our findings can be
extrapolated to patients presenting to primary care. Third, we
cannot comment on patients who present >12 hours after
symptom onset because these patients were excluded from our
study. However, only a few patients presented >12 hours after
the syncopal event. Fourth, prohormone levels were measured
once. Further studies are warranted to evaluate whether serial
sampling would allow a further increase in diagnostic accuracy.
Fifth, despite using the most stringent and unprecedented
method of central adjudication of the final diagnosis by 2
independent cardiologists who had access to the whole clinical
workup and the study-specific data set, third-party anamnesis,
and long-term follow-up of cardiovascular events and/or
recurrent syncope, a few patients may still have been misclas-
sified. This invariablymay lead to a slight underestimation of the
true accuracy of the prohormones tested.
In conclusion, this large multicenter diagnostic study
suggests that the plasma level of MRproANP may be a
quantitative marker of cardiac syncope. Using it in conjunc-
tion with the ED probability, summarizing all information
commonly available at 90 minutes in the ED, including the
12-lead ECG, improves the early rule out and/or rule in of
cardiac syncope. In contrast, the other prohormones tested
did not seem to have diagnostic utility.
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 Data S1. 
SUPPLEMENTAL METHODS 
Adjudication of the final diagnosis 
The first step in the adjudication process was to decide whether there was syncope or 
not. If the criteria for a true syncope were not fulfilled, a distinction between the 
following non-syncopal disorders was made: pre-syncope; falls; stroke/TIA; epilepsy; 
metabolic disorders: e.g. hypoglycaemia, hypoxia, hyperventilation; intoxication: e.g. 
alcohol, benzodiazepines, opiates; functional (psychogenic pseudosyncope); others. 
The classification of syncope is based on pathophysiological considerations. The 
following predefined differential diagnoses were used:1,2 
 
1) Cardiac syncope: We distinguished between: 
 
a. Arrhythmia as primary cause: Arrhythmias are the most common 
cause of syncope; Bradycardia: sinus node dysfunction, 
atrioventricular conduction system disease, implanted device 
malfunction or drug-induced; Tachycardia: supraventricular or 
ventricular. 
b. Structural heart disease: structural heart diseases can cause 
syncope when circulatory demands outweigh the impaired ability of 
the heart to increase output. However, in some cases syncope may 
not solely be the result of restricted cardiac output, but be in part 
due to an inappropriate reflex. However, when a structural heart 
disease was the primary cause or contributed most to syncope, it 
was classified as cardiovascular syncope. 
c. Others: pulmonary embolism, acute aortic dissection, pulmonary 
hypertension or any other cause for a cardiovascular syncope. 
 2) Reflex (neutrally-mediated) syncope: This syncope is characterized by 
cardiovascular reflexes which are normally useful in controlling circulation 
but become intermittently inappropriate in response to a trigger. The reflex 
results in vasodilation and/or bradycardia which lead to a fall in arterial blood 
pressure and consequently to cerebral hypoperfusion. Identifying a trigger is 
central when diagnosing a reflex syncope. Typically symptoms as light- 
headedness, nausea, sweating, weakness or visual disturbances precede 
reflex syncope. We distinguished between: 
a. Vasovagal: “common faint”, triggered by emotional distress/ pain or 
mediated by orthostatic stress. 
b. Situational: refers to reflex syncope associated with some specific 
circumstances, e.g. post-micturition, post-prandial, gastrointestinal 
stimulation, cough. 
c. Carotid sinus syncope: triggered by mechanical manipulation of the 
carotid sinus. It can be diagnosed by carotid sinus massage. 
d. Atypical forms: reflex syncope occurring with uncertain or apparently 
absent triggers. 
3) Syncope due to orthostatic hypotension: Orthostatic hypotension is defined 
as an abnormal decrease in systolic blood pressure after changing from 
supine to standing position. Key can be syncope immediately after 
standing up or a pathological Schellong test. We distinguished between: 
a. Primary autonomic failure: There is an autonomic failure which is 
clearly a primary part of Parkinson syndrome as idiopathic 
Parkinson disease or atypical Parkinson syndrome (multiple system 
 atrophy, progressive supranucleair oculomotoric paresis, 
corticobasal degeneration or lewy body dementia). 
b. Secondary autonomic failure: autonomic failure may be due to 
circumstances such as diabetes, uraemia, amyloidosis or spinal 
cord injuries 
c. Drug-induced orthostatic hypotension: orthostatic hypotension is 
due to drugs which can lead to orthostatic hypotension such as 
diuretics, antidepressants, vasodilators, alcohol 
d. Volume depletion: orthostatic hypotension is caused by a 
hypovolemia due to haemorrhage, diarrhoea, vomiting or fever 
e. Others: sometimes the pathophysiology remains unclear. 
 
4) Others, non-cardiac syncope: Sometimes the underlying 
pathophysiological mechanism of syncope remains unclear, but a cardiac 
syncope is ruled-out. 
5) Syncope of unknown etiology (cardiac syncope possible): the etiology of 
syncope still remained unknown and a cardiac syncope was considered to 
be a possible cause. 
 EGSYS risk score – Multivariate2,1 
 
The point score is found as the sum of the following risk factors: 
 
- Palpitations: 4 
 
- Abnormal ECG/Cardiopathy: 3 
 
- Effort Syncope: 3 
 
- Syncope in supine position: 2 
 
- Neurovegetative prodromes: -1 
 
- Precipitating and predisposive factors: -1 
 
A score greater than 2 implies an increased risk for cardiac syncope. 
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Test done (%) 
ECG 666 (97) 
Carotid Duplex 50 (7) 
Cranial CT 208 (30) 
TTE 229 (33) 
X-Ray Chest 322 (47) 
EEG 46 (7) 
Ergometry 23 (3) 
Holter-ECG 111 (16) 
Telemetry 131 (19) 
Loop Recorder 7 (1) 
Coronary Angiography 33 (5) 
MPI 9 (1) 
Schellong 290 (43) 
 
*ECG = Electrocardiogram; Cranial CT = Cranial computed tomography; TTE = Transthoracic 
echocardiography; EEG = Electroencephalogram; MPI = Myocardial perfusion imaging. 
 Table S3. All final adjudicated diagnoses, n (%) 
 
Cardiac Syncope 125 (18.1) 
Arrhythmia as primary cause 
Bradycardia 
Sinus node dysfunction 
AV conduction system disease 








Secondary to structural heart disease 
Drug-induced 
Unknown 
Structural Heart Disease 
Cardiac valvular disease 
Acute myocardial infarction/ischaemia 
Hypertrophic cardiomyopathy 
Congenital anomalies of coronary arteries 








































Reflex (neurally-mediated) syncope 320 (46.4) 
Vasovagal 157 (22.8) 
Mediated by emotional distress/pain 104 (15.1) 
Mediated by orthostatic stress 53 (7.7) 
Situational 116 (16.8) 
Cough, Sneeze 6 (0.9) 
Gastrointestinal stimulation 63 (9.1) 
Post-prandial 28 (4.1) 
Post-micturition 10 (1.5) 
Others 9 (1.3) 
Carotid sinus syncope 2 (0.3) 
Atypical forms (without apparent triggers or atypical presentation) 45 (6.5) 
Syncope due to orthostatic hypotension 181 (26.3) 
 Primary autonomic failure 6 (0.9) 
Pure autonomic failure 0 (0) 
Multiple system atrophy 0 (0) 
Lewy body dementia 0 (0) 
Parkinson's disease with autonomic failure 6 (0.9) 
Others 0 (0) 
Secondary autonomic failure 6 (0.9) 
Diabetes mellitus 2 (0.3) 
Amyloidosis 0 (0) 
Uraemia 0 (0) 
Spinal Cord Injuries 0 (0) 
Others 4 (0.6) 
Drug-induced orthostatic hypotension 66 (9.6) 
Alcohol 8 (1.2) 
Phenothiazines 2 (0.3) 
Vasodilators 23 (3.3) 
Diuretics 15 (2.2) 
Antidepressants 6 (0.9) 
Others 20 (2.9) 
Volume Depletion 72 (10.4) 
Haemorrhage 6 (0.9) 
Diarrhoea 6 (0.9) 
Vomiting 2 (0.3) 
Fever/SIRS 40 (5.8) 
Others 18 (2.6) 
Others 31 (4.5) 
Others (but no cardiac syncope) 63 (9.1) 
 Table S4. Reclassification by means of MRproANP 
 













VAS & MRproANP 
0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71-80% 81-90% 91-100% % 
225 21 1 2 1 0 0 0 0 0 10 
3 68 17 3 1 3 0 0 0 1 29 
0 3 44 10 2 2 0 0 0 0 28 
0 0 3 28 1 2 0 0 0 0 16 
0 0 0 8 25 9 1 1 0 0 75 
0 0 0 0 5 10 2 1 0 0 44 
0 0 0 0 0 2 10 1 0 1 29 
0 0 0 0 0 0 10 13 3 2 54 
0 0 0 0 0 0 0 1 5 4 50 
0 0 0 0 0 0 0 0 3 6 33 













VAS & MRproANP 
0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71-80% 81-90% 91-100% % 
6 2 1 1 0 0 0 0 0 0 40 
0 0 1 0 0 0 0 0 1 0 100 
0 0 4 3 0 0 0 0 0 0 43 
0 0 0 1 3 0 1 0 0 0 60 
0 0 0 0 1 2 1 0 0 1 80 
0 0 0 0 0 7 1 1 0 0 22 
0 0 0 0 0 0 4 2 0 1 43 
0 0 0 0 0 0 2 9 8 2 57 
0 0 0 0 0 0 0 2 8 15 68 
0 0 0 0 0 0 0 0 4 30 12 
  
Net reclassification improvement focuses on reclassification tables constructed separately for participants without events (non-cardiac syncope) 
and patients with events (cardiac syncope), and quantifies the balance between correct movements in categories (upwards for events and 
downwards for non-events) and incorrect movements (downwards for events and upwards for non-events) 
The biggest incremental value of MRproANP is seen in patients with intermediate risk of cardiac syncope, determined by the 
ED-physician with a visual analogue score (VAS) ranging between 21%-80%. In patients with non-cardiac syncope, 31 (5.5%) correctly moved 
downward in the classification and 38 patients (6.7%) incorrectly moved upward. In patients with cardiac syncope, 26 patients (21%) correctly 
moved upwards and 2 (1.6%) incorrectly moved downward in the classification. 
The net reclassification improvement was calculated at 0.216 (p<0.001). Integrated discriminatory improvement (IDI) was 0.035 (p=0.001). 
  
Table S5. Overview of patients with low initial ED-probability (VAS-Score ≤20%) and a final diagnosis of cardiac syncope 
 
Age Sex VAS (%) Prodromi Situation ECG MRproANP (ng/L) Diabetes HT HC Smoking ARRH History of MI Valvular Epilepsy 
77 male 10 No Sitting normal 106 No No Yes No Yes No No No 
44 female 10 Yes Standing normal 121 No No No No No No No No 
79 male 10 Yes Standing normal 187 No No Yes No Yes No No No 
86 female 0 Yes Sitting normal 196 Yes No Yes No No No No No 
70 male 20 No Exertion abnormal 256 No No No No No No No No 
80 female 10 Yes Sitting abnormal 262 No No Yes No No No No No 
61 male 0 No Standing normal 275 No Yes No Yes No Yes No No 
76 male 0 Yes Standing abnormal 295 No Yes Yes Yes No Yes No No 
85 female 10 No Standing abnormal 451 No No No No Yes No No No 
80 male 0 Yes Standing abnormal 682 Yes Yes Yes Yes Yes Yes Yes No 
71 female 20 Yes Standing normal 1142 No No Yes Yes No No No No 
VAS = Visual analogue scale; Prodromi = Blurred Vision, Sweating or Dizziness; ECG = Electrocardiogram; HT = Hypertension; HC = 
Hypercholesterolemia; ARRH = Arrhythmia; MI = Myocardial Infarction; Valvular: Valvular heart disease. 
 Figure S1. Patient flow diagram for all patients. 
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